Download MendeleyFragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90
Buchstaller, H.-P., Eggenweiler, H.-M., Sirrenberg, C., Graedler, U., Musil, D., Hoppe, E., Zimmermann, A., Schwartz, H., Maerz, J., Bomke, J., Wegener, A., Wolf, M.(2012) Bioorg Med Chem Lett 22: 4396-4403
- PubMed: 22632933
- DOI: https://doi.org/10.1016/j.bmcl.2012.04.121
- Primary Citation of Related Structures:
4EEH, 4EFT, 4EFU - PubMed Abstract:
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe the identification of novel small molecular weight inhibitors of Hsp90 using a fragment based approach. Fragments were selected by docking, tested in a biochemical assay and the confirmed hits were crystallized. Information gained from X-ray structures of these fragments and other chemotypes was used to drive the fragment evolution process. Optimization of these high ¦̀M binders resulted in 3-benzylindazole derivatives with significantly improved affinity and anti-proliferative effects in different human cancer cell lines.
Organizational Affiliation:
Merck Serono Research, Merck KGaA, Frankfurter Stra?e 250, D-64293 Darmstadt, Germany. hans-peter.buchstaller@merckgroup.com
